Progress in the treatment of advanced hepatocellular carcinoma with immune combination therapy

Table 2 Clinical Trials of hepatocellular carcinoma immunotherapy completed in the last five years (ClinicalTrials.gov)

NCT ID	Study phase	Patient population	Intervention measures	Region
NCT04393220	II	Advanced HCC	Bevacizumab + Nivolumab	China
NCT03785210	II	Primary HCC or liver dominant metastatic cancer from colorectal or pancreatic cancers	Nivolumab + Tadalafil + Vancomycin	United States
NCT03939975	II	Advanced HCC	Pembrolizumab/Nivolumab/JS001	China
NCT04172506	I/II	Advanced solid tumors	AK105	China
NCT03419897	II	Previously treated HCC unresectable carcinoma	Atezolizumab	China, Europe
NCT05471674	II	Borderline resectable HCC	Nivolumab	China
NCT03980288	I	Advanced HCC	CAR-GPC3 T Cell	China
NCT03841110	I	Advanced solid tumors	FT500/FT500 + Nivolumab/FT500 + Pembrolizumab/FT500 + Atezolizumab/FT500 + IL-2 + Nivolumab/FT500 + IL-2 + Pembrolizumab/FT500 + IL-2 + Atezolizumab	United States
NCT04161911	NA	Advanced HCC	Nivolumab	United States
NCT03735628	I	Advanced solid tumors	Copanlisib + Nivolumab	United States, Canada
NCT04310709	II	Unresectable or metastatic HCC	Regorafenib/Nivolumab	Korea
NCT03299946	I	Locally advanced HCC	Cabozantinib/Nivolumab	United States
NCT05535998	Retrospective study	HCC with portal vein tumor thrombus	TACE-HAIC + TKIs + PD-1 inhibitors/TACE	China
NCT03849469	I	Advanced solid tumors	Pembrolizumab	United States
NCT03652077	I	Advanced solid tumors	INCAGN02390 (TIM3 inhibitors)	United States

HCC: Hepatocellular carcinoma; NA: Not available; TACE: Transcatheter arterial chemoembolization; NCT: National clinical trials; HAIC: Hepatocellular arterial infusion chemotherapy; TKIs: Tyrosine kinase inhibitors; PD-1: Programmed cell death protein 1; IL: Interleukin.